Analyst Ratings
Here’s a quick summary of recent ratings and price targets for Psykey and ResMed, based on MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Psykey | 0 | 0 | 0 | 0 | N/A |
| ResMed | 1 | 5 | 6 | 1 | 2.54 |
ResMed’s average target price is $218.18, indicating a possible drop of 9.09%. Analysts favor ResMed over Psykey due to its higher upside potential.
Ownership
Institutional investors hold 55.0% of ResMed shares, while insiders hold 1.2%. Strong institutional ownership suggests confidence in long-term performance.
Financial Comparison
This table shows key financial metrics for Psykey and ResMed.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share (EPS) | Price/Earnings Ratio | |
| Psykey | N/A | N/A | N/A | ($0.41) | -0.05 |
| ResMed | $4.69 billion | 7.53 | $1.02 billion | $6.51 | 36.87 |
ResMed leads in revenue and earnings compared to Psykey but is priced higher regarding earnings ratio.
Profitability Metrics
| Net Margins | Return on Equity | Return on Assets | |
| Psykey | N/A | N/A | N/A |
| ResMed | 21.79% | 25.00% | 16.67% |
Summary
ResMed outperforms Psykey in all metrics assessed.
About Psykey
Psykey, Inc. focuses on researching and developing herbal and nootropic products aimed at enhancing everyday life. The company, originally named CeCors, Inc., was rebranded in August 2021. It was founded in 2002 and is based in Toronto, Canada.
About ResMed
ResMed Inc. manufactures and sells medical devices and software for respiratory care. Founded in 1989, it is headquartered in San Diego, California.
Get Daily News & Ratings for Psykey – Enter your email below for a concise daily summary of news and analyst ratings of Psykey and similar companies with MarketBeat.com’s FREE daily newsletter.
`
